---
title: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease
date: '2024-10-25'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39453837/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20241026190550&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: In a broad range of patients with chronic kidney disease
  at risk for progression, empagliflozin continued to have additional cardiorenal
  benefits for up to 12 months after it was discontinued. (Funded by Boehringer Ingelheim
  and others; EMPA-KIDNEY ClinicalTrials.gov number, NCT03594110; EuDRACT number,
  ...'
disable_comments: true
---
CONCLUSIONS: In a broad range of patients with chronic kidney disease at risk for progression, empagliflozin continued to have additional cardiorenal benefits for up to 12 months after it was discontinued. (Funded by Boehringer Ingelheim and others; EMPA-KIDNEY ClinicalTrials.gov number, NCT03594110; EuDRACT number, ...